Interleukin-6 and rheumatic diseases

Arthritis Research and Therapy

Volumn 8, Issue SUPPL. 2, 2006, Pages

  Lipsky, Peter E ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATLIZUMAB; C REACTIVE PROTEIN; HEPCIDIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MR16-1; PLACEBO; RECOMBINANT INTERLEUKIN 6; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; GLYCOPROTEIN GP 130; HEMOGLOBIN; INTERLEUKIN 6 RECEPTOR ALPHA; TOCILIZUMAB;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; HUMAN; IMMUNOPATHOGENESIS; JUVENILE RHEUMATOID ARTHRITIS; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RHEUMATIC DISEASE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; ANEMIA; AUTOIMMUNE DISEASE; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MODEL; DRUG DOSE ESCALATION; DRUG MECHANISM; EXPERIMENTAL MODEL; IMMUNE RESPONSE; INFLAMMATION; INHIBITION KINETICS; MONKEY; PATHOPHYSIOLOGY; PLEIOTROPY; PROTEIN INTERACTION; RHEUMATOID ARTHRITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; METABOLISM; RHEUMATIC DISEASES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-6; RHEUMATIC DISEASES; SIGNAL TRANSDUCTION;

EID: 33748092926     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1918     Document Type: Article

References (38)

1. Van Snick J: Interleukin-6 an overview. Annu Rev Immunol 1990, 8:253-278.
2. Romano MM, Sironi C, Toniatti N, Polentarutti N, Fruscella P, Ghezzi R, Faggioni W, Luini V, van Hinsbergh S, Sozzani S, et al.: Role of IL-6 and its soluble receptor in induction of chemokines; and leukocyte recruitment Immunity 1997, 6:315-325.
3. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y: Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol 1995, 34: 321-325.
4. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T: Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Nad Acad Sci USA 1993, 90:11924-11928.
5. Chai Z, Gatti S, Toniatti C, Poli V, Bartfaii T: IL-6 gene expression in the CNS is necessary for fever response to LPS or IL-1β: a study on IL-6-deficient mice. J Exp Med 1996, 183: 311-316.
6. Streetz KL, Wustefeld T, Klein C, Manns MP, Trautwein C: Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-Le-Grand) 2001, 47:661-673.
7. Kopf M, Le Gros G, Coyle AJ, Kosco-Vilbois M, Brombacher F: Immune response of IL-4, IL-5, IL-6 deficient mice. Immunol Rev 1995, 148:45-70.
8. Takai Y, Seki N, Senoh H, Yokota T, Lee F, Hamaoka T, Fujiwara H: Enhanced production of interleukin-6 in mice with type II collagen-induced arthritis. Arthritis Rheum 1989, 32:594-600.
9. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, De Benedetti F, Poli V, Ciliberto G: Interleukin-6 is required for the development of collagen-induced arthritis. J Exp Med 1998, 187:461-468.
10. Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, Williams AS, Jones SA: Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 2003, 171:3202-3209.
11. Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G, Dayer JM, Vischer T, Guerne A: Concentrations and origins of soluble interleukin 6 receptor-a in serum and synovial fluid. J Rheumatol 1997, 24:1510-1516.
12. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, Yamaguchi A, Kishimoto T, Suda T, Kashiwazaki S: Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996, 11:88-95.
13. Takagi N, Mihara M, Moriya Y, Nishimoto N, Yoshizaki K, Kishimoto T, Takeda Y, Ohsugi Y: Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 1998, 41:2117-2121.
14. Ding C, Jones G: Technology evaluation: MRA, Chugai. Curr Opin Mol Ther 2003, 5:64-69.
15. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM: Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993, 53:851-856.
16. Mihara M, Kotoh M, Nishimoto N, Oda Y, Kumagai E, Takagi N, Tsunemi K, Ohsugi Y, Kishimoto T, Yoshizaki K, Takeda Y: Humanized antibody to human interleukin-6 receptor inhibits the development of coliagen arthritis in cynomolgus monkeys. Clin Immunol 2001, 98:319-326.
17. Madhok R, Crilly A, Watson J, Capell HA: Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993, 52:232-234.
18. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, et al.: Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002, 46:3143-3150.
19. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, Nishimoto N, Yoshizaki K, Kishimoto T: Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005, 52:818-825.
20. Ripley BJ, Goncalves B, Isenberg DA, Latchman DS, Rahman A: Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemnia. Ann Rheum Dis 2005, 64:849-853.
21. Leng S, Chaves P, Koenig K, Walston J: Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc 2002, 50: 1268-1271.
22. Nieken J, Mulder NH, Buter J, Vellenga E, Limburg PC, Piers DA, de Vries EG: Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood 1995, 86:900-905.
23. Sun WH, Binkley N, Bidwell DW, Ershler WB: The influence of recombinant human interleukin-6 on blood and immune parameters in middle-aged and old rhesus monkeys. Lymphokine Cytokine Res 1993, 12:449-455.
24. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata. T, Kawai H, Tagoh H, Komori T, et al.: Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989, 74:1360-1367.
25. Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M: Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol 2005, 28:231-238.
26. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, et al.: Randomised clinical trial of the IL-6 receptor antagonist tocilizumab (MRA), in rheumatoid arthritis patients with an incomplete response to methotrexate in Europe (CHARISMA). Arthritis Rheum 2006:in press.
27. Andrews NC: Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004, 113:1251-1253.
28. Nemeth E, Rivera S, Gabayan V, Keller C, TaudorF S, Pedersen BK, Ganz T: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004, 113:1271-1276.
29. Compston JE, Vedi S, Croucher PI, Garrahan NJ, O'Sullivan MM: Bone turnover in non-steroid treated rheumatoid arthritis. Ann Rheum Dis 1994 53:163-166.
30. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA: Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003, 32:1-7.
31. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000, 148:209-214.
32. Woods A, Brull DJ, Humphries SE, Montgomery HE: Genetics of inflammation and risk of coronary artery disease: the central role of interleukin 6. Eur Heart J 2000, 21:1574-1583.
33. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999, 106:506-512.
34. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
35. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH: Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998, 98:731-733.
36. Kuller LH, Tracy RP, Shaten J, Meilahn EN for the MRFIT Research Group: Relationship of C-reactive protein and coronary heart disease in the MRIFIT nested case-control study. Am J Epidemiol 1996, 144:537-547.
37. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM: Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002, 22:1668-1673.
38. Lindmark E, Diderholm E, Wallentin L, Siegbahn A: Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease. Effects of an early invasive or noninvasive strategy. JAMA 2001, 286:2107-2113.